Search Results - james+gulley

3 Results Sort By:
Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies
Summary: The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a liquid biopsy diagnostic assay capable of detecting loss of heterozygosity (LOH) and somatic mutations in genes important for antigen processing and presentation and interferon-γ response pathways. Description of Technology: Immunotherapy is...
Published: 12/9/2024   |   Inventor(s): Scott Norberg, Andrew Sinkoe, Xiaolin Wu, James Gulley
Keywords(s):  
Category(s): Application > Diagnostics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology
Methods of Detecting Loss of Heterozygosity and Damaging Mutations in Immune-Related Genes Using Liquid Biopsies
Summary: The National Cancer Institute (NCI) seeks co-development partners and/or licensees for a liquid biopsy diagnostic assay capable of detecting loss of heterozygosity (LOH) and somatic mutations in genes important for antigen processing and presentation and interferon-γ response pathways. Description of Technology: Immunotherapy is...
Published: 12/20/2024   |   Inventor(s): Scott Norberg, Andrew Sinkoe, Xiaolin Wu, James Gulley
Keywords(s):  
Category(s): Application > Diagnostics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, TherapeuticArea > Immunology, Collaboration Sought > Licensing
Method for HLA LOH Detection in Liquid Biopsies
Abstract: Human leukocyte antigen (HLA) LOH (LOH) is a known resistance mechanism by which cancers evade T cell receptor-(TCR-)based immunotherapies. This class of therapies includes immune checkpoint inhibition (ICI, e.g., Pembrolizumab), engineered TCR (T cell receptor)-T cell adoptive transfer, tumor infiltrating lymphocytes (TIL), T-cell engagers,...
Published: 12/17/2024   |   Inventor(s): Andrew Sinkoe, James Gulley, Cem Sievers
Keywords(s): Companion Diagnostic, Gulley, HLA, Human Leukocyte Antigen, ICI, Immune Checkpoint Inhibition, Immunotherapy, LOH, Loss of Heterozygosity, Sinkoe, T cell therapy
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Diagnostics